Ascletis Pharma Inc.

Investors

Voluntary Announcement - Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication
2021-06-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
2021-06-02
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
2021-05-27
Form of Proxy for the 2021 Annual General Meeting
2021-05-27
Notice of 2021 Annual General Meeting
2021-05-27
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-election of Retiring Directors and Notice of Annual General Meeting
2021-05-27
Voluntary Announcement - Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication
2021-05-27
Voluntary Announcement - Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA
2021-05-25
Voluntary Announcement - Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
2021-05-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
2021-05-04

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号